Cost‐effectiveness of continuous glucose monitoring in Chinese adults with uncontrolled type 2 diabetes: A modelling study stratified by baseline HbA 1c
Authors' conclusion
CGM represents a cost-effective intervention for Chinese adults with uncontrolled T2D, demonstrating enhanced economic value in populations with elevated baseline HbA1c levels. Implementing risk-stratified reimbursement policies coupled with price negotiations aligned with evidence-based cost thresholds ($1920-$2316 annually), may optimize healthcare resource allocation.
Study context
- Population
- Simulated Chinese adults with uncontrolled T2D, cohorts with baseline HbA1c 7.70%, 8.70%, 9.70% and 10.70%; efficacy data from meta-analyses
- Comparison
- CGM vs self-monitoring of blood glucose (SMBG)
- Outcome
- Incremental cost-effectiveness ratio (cost per quality-adjusted life year (QALY) gained) vs WTP threshold of $40 344 per QALY (3× China's per capita gross domestic product (GDP))
- Follow-up
- 30 years
Methodological detailsUKPDS Outcomes Model version 2, 30-year simulation, China's healthcare perspective, sensitivity and scenario analyses
- UKPDS Outcomes Model version 2
- 30-year simulation
- China's healthcare perspective
- Sensitivity and scenario analyses
Main finding
As reported in the abstract
Incremental cost-effectiveness ratios (ICERs) across baseline HbA1c 7.70%-10.70%, all below willingness-to-pay (WTP) threshold
$29 428 to $38 819 per QALY gained
Further findings
Probabilistic sensitivity analysis
- Cost-effectiveness probability, all cohorts
- >96%
- CGM utility benefits and device costs were key drivers
Annual CGM cost thresholds for cost-effectiveness
- Threshold range by baseline HbA1c 7.70%-10.70%
- $1920 to $2316
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →